SCHEMBL22445500

SCHEMBL22445500

CON(C)C(=O)Cc1ccc(C)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 2/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.37
▸ DAO P14920 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ MITF O75030 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ MRGPRX4 Q96LA9 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ PTGS1 P23219 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ POLB P06746 1/20 0.36
▸ APEX1 P27695 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ KMT2A Q03164 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ GPR183 P32249 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515850 0.88 HDAC4 (0.45) HDAC6HDAC4KDM4EMITFALDH1A1
SCHEMBL18912182 0.84 PARP1 (0.43) HDAC6HDAC4HDAC1DAOALDH1A1
SCHEMBL22607853 0.82 HPGD (0.41) HDAC6HDAC4HDAC1ALDH1A1PTGS1
SCHEMBL4440407 0.81 KDM4E (0.43) HDAC6HDAC4HDAC1KDM4EALDH1A1
SCHEMBL8045889 0.79 HDAC4 (0.45) HDAC6HDAC4KDM4EMITFALDH1A1
SCHEMBL1399311 0.79 TDP1 (0.56) HDAC6HDAC4KDM4EALDH1A1HTT
SCHEMBL30965121 0.79 RAB9A (0.43) HDAC6HDAC4KDM4EALDH1A1PTGS1
SCHEMBL19181646 0.79 SKP2 (0.41) HDAC6HDAC4KDM4EALDH1A1PTGS1
SCHEMBL1555409 0.78 ALDH1A1 (0.53) HDAC6HDAC1ALDH1A1KMT2A
SCHEMBL8064820 0.77 HDAC4 (0.49) HDAC6HDAC4POLBAPEX1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351577-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) FORMA THERAPEUTICS, INC. (US) 2025-07-08 — — US disclosed
US-20250188079-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. 2025-06-12 — — US disclosed
US-20220213089-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. 2022-07-07 — — US disclosed
US-20220213089-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. 2022-07-07 — — US disclosed
EP-3937940-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) Forma Therapeutics, Inc. (US) 2022-01-19 — — EP disclosed
WO-2020190791-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) FORMA THERAPEUTICS, INC. (US) 2020-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188079-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) CREBBP, CREB1, EP300 HDAC6 299/4885HDAC4 137/4885HDAC1 25/4885
US-12351577-B2 Inhibiting cyclic AMP-responsive element-binding protein (CREB) CREBBP, CREB1, EP300 HDAC6 299/4885HDAC4 137/4885HDAC1 25/4885
US-20220213089-A1 INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) CREBBP, CREB1, EP300 HDAC6 299/4885HDAC4 137/4885HDAC1 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback